Consistently, patients with higher ATP5B expression in the TCGA and METABRIC datasets also had worse overall survival outcomes (Figure 4B) and four cohorts (GSE1456-GPL96, GSE3494-GPL96, GSE4922-GPL96, and GSE7390) by using PrognoScan, including different endpoints for breast cancer patients, showed that higher ATP5B expression was associated with an unfavorable prognosis (Table 3). Here, ATP5F1B is linked to breast carcinoma.